Inclusion Criteria:  Aged 18 years or older female； ECOG score 0-1; Life expectancy is not less than 12 weeks; Histology confirmed HR-positive and HER2-negative locally advanced or metastatic breast cancer; Premenopausal women have taken effective ovarian function suppression methods, such as drug suppression or ovariectomy; At least one objectively measurable breast cancer lesions according to RECIST 1.1 ; No more than one systemic chemotherapy for metastatic disease; Disease relapse within 12 months after at least 24 months endocrine adjuvant therapy, or disease progress after at least 6 months endocrine salvage therapy; Normal function of main organs and bone marrow: Hemoglobin≥90g/L; Neutrophil count (ANC)≥1.5×109/L; Platelet count (PLT)≥80×109/L; Total bilirubin≤1.5×ULN (upper limit of normal); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN (≤5×ULN if has liver metastasis); Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance ≥60mL/min (Cockcroft-Gault formula); Sign the informed consent;  Exclusion Criteria:  Have received prior fulvestrant or anti-angiogenic drug treatment, or known to be allergic to any excipients in the study; Visceral crisis; Uncontrolled or high-burden CNS metastases; Unable to swallow; Abnormal coagulation function; Tumor has invaded important blood vessels and may cause fatal bleeding; Pleural effusion or pericardial effusion that requiring repeated drainage; Hypertension that cannot be well controlled by a single antihypertensive drug; Unstable angina, myocardial infarction within 6 months, serious arrhythmias; The history of immunodeficiency, including HIV or other obtained or congenital immunodeficiency diseases, or a history of organ transplantation; Poorly controlled diabetes; Abnormal urine protein, and the 24-hour quantification suggests urine protein ≥1.0g; Bleeding constitution or medical history Unhealed wounds, ulcers or fractures; Have arterial/venous thrombotic events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism; In other clinical trials of anti-tumor drugs simultaneously; Other concomitant disease or disability that endangers safety according to the judgment of investigator;